TrialAnnals of hematology2018

Outcomes of switching to dasatinib after imatinib-related low-grade adverse events in patients with chronic myeloid leukemia in chronic phase: the DASPERSE study.

Dong-Wook Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.